Reviewed listing: NASDAQ:ARWR · Analysis dated Oct 21, 2026
It has not been confirmed whether the basis of this analysis still holds today. Read it as a dated earlier assessment; it does not establish a current buying opportunity.
How does the company make money?
Arrowhead develops medicines that silence specific disease-causing genes. REDEMPLO is already being sold to treat a rare lipid disorder.
What supports the business?
A first approved drug and agreements with major pharmaceutical partners show that research can be put to commercial use.
What could improve?
Approval for additional patient groups could help REDEMPLO grow. Other active ingredients may be added, but still have to prove their efficacy and safety.
How is the stock price assessed?
This assessment refers to the analysis and its quoted price shown here. It is not a live quote or a personal recommendation to buy.
58.92 USD do not represent a sufficiently substantiated attractive entry point today. The stock is valued at around 8.32 billion USD, despite the company still incurring substantial losses.
What is the main risk?
Studies or launches may disappoint while research and sales continue to require substantial funding. New financing may reduce existing shareholders' ownership stakes.
What is the overall assessment?
Arrowhead sells its first drug, REDEMPLO, and has a broad research base. Current product sales remain small relative to high development costs. At 58.92 USD, the price assumes substantial future success; an attractive valuation has not yet been sufficiently established. Watch.
Continue exploring this stock in your account
A free Marqora account gives you the detailed analysis with further evidence and lets you compare and save stocks. Your selected stock is kept when you sign in or register.
Open the full analysis in a free account →
Already have an account? Sign in